<DOC>
	<DOCNO>NCT00345189</DOCNO>
	<brief_summary>This open-label , multicenter , dose-escalation , safety , pharmacokinetics , pharmacodynamics study .</brief_summary>
	<brief_title>Study Oral CNF2024 ( BIIB021 ) Advanced Solid Tumors</brief_title>
	<detailed_description>Heat shock protein 90 ( Hsp90 ) ubiquitous molecular chaperone protein involve folding , activation , assembly many protein , include key mediator signal transduction , cell cycle control , transcriptional regulation . In cancer cell dependent upon Hsp90 client protein , degree client inhibit correlate closely induction growth inhibition apoptosis Hsp90 inhibitory drug . The active pharmaceutical ingredient CNF2024 , CF1983 mesylate , synthetic , new chemical entity design inhibit Hsp90 . CF1983 hada strong affinity tumor derive Hsp90 weak affinity Hsp90 isolate normal cell recombinant Hsp90 .</detailed_description>
	<criteria>Histologically cytologically confirm solid tumor fail standard therapy ( surgery , radiotherapy , endocrine therapy , chemotherapy ) effective therapy available At least 18 year age Hematology : Absolute neutrophil count ( ANC ) &gt; 1500 cells/mm3 , platelet count &gt; 100,000 cells/mm3 hemoglobin &gt; = 9 gm/L Hepatic : Bilirubin &lt; 1.5 X upper limit normal ( ULN ) ; alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 X ULN . Patients know liver metastasis liver neoplasm : alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 5.0 X ULN . Renal : Serum creatinine level &lt; 2.0 mg/dL creatinine clearance &gt; 60 mL/min Coagulation : international normalized ratio ( INR ) &lt; 1.5 time normal Adrenal : Normal plasma cortisol adrenocorticotropic hormone ( ACTH ) level Normal electrocardiogram ( ECG ) QTc &lt; = 450 msec men &lt; = 470 msec woman Estimated life expectancy least 3 month determine Investigator Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; = 2 Male female patient childbearing potential must practice effective doublebarrier contraception study continue contraception 3 month last dose study drug . Male patient must agree intercourse pregnant nursing woman study 3 month last dose study drug , unless use doublebarrier contraception . The exception doublebarrier contraception : Patient partner surgically sterile , female patient postmenopausal least 1 year screen patient abstains sexual intercourse , discretion Investigator Pregnant nursing woman , woman childbearing age use reliable mean contraception . Radiotherapy chemotherapy within previous 28 day . Recovery Grade 1 less chemotherapyinduced toxic effect , except alopecia , require . Participation investigational drug study within 28 day prior CNF2024 administration Active infection require intravenous antibiotic treatment Patients second malignancy require active treatment ( except hormonal therapy ) Concurrent severe uncontrolled medical disease ( i.e. , systemic infection , diabetes , hypertension , coronary artery disease , congestive heart failure ) Active symptomatic fungal , bacterial and/or viral infection include active HIV viral ( A , B C ) hepatitis Problems swallow malabsorption Chronic diarrhea ( excess 23 stools/day normal frequency ) Gastrointestinal diseases include gastritis , ulcerative colitis , Crohn 's disease , hemorrhagic coloproctitis Major surgery stomach small intestine Adrenal dysfunction &gt; Grade 2 Patients diabetes ( doctor discus eligible study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Hsp90 inhibitor</keyword>
	<keyword>CNF2024</keyword>
	<keyword>Advanced Solid Tumors</keyword>
</DOC>